This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Pediatrics  • Adolescent Medicine  • Psychiatry  • Depression  • Alert me on articles by topic  Social Bookmarking   What's this?

Christopher K. Varley, MD

JAMA. 2003;290:1091-1093.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The report by Wagner and colleagues¹ in this issue of THE JOURNAL, a pooled analysis of 2 multicenter, double-blind, randomized placebo-controlled trials evaluating the effect of the selective serotonin reuptake inhibitor (SSRI) sertraline on children and adolescents aged 6 to 17 years with major depressive disorder (MDD), constitutes the largest positive psychopharmacological study of MDD in this age group reported to date. The primary outcome was change from baseline in the Children's Depression Rating Scale–Revised (CDRS-R), with a prospectively determined primary efficacy measure of the CDRS-R Best Description of Child total score; secondary efficacy measures included the proportion of CDRS-R responders, defined as patients who had at least a 40% decrease in the adjusted CDRS-R total score. The results indicate a statistically significant improvement for patients receiving active drug vs those receiving placebo.

An increasing body of knowledge confirms that depression is a common and serious . . . [Full Text of this Article]

Author Affiliation: Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Efficacy of Sertraline in the Treatment of Children and Adolescents With Major Depressive Disorder: Two Randomized Controlled Trials
Karen Dineen Wagner, Paul Ambrosini, Moira Rynn, Christopher Wohlberg, Ruoyong Yang, Michael S. Greenbaum, Ann Childress, Craig Donnelly, and Deborah Deas
JAMA. 2003;290(8):1033-1041.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

US Suicide Rates by Age Group, 1970-2002: An Examination of Recent Trends
McKeown et al.
AJPH 2006;96:1744-1751.
ABSTRACT | FULL TEXT  

Posttraumatic Stress and Depressive Symptoms, Alcohol Use, and Recurrent Traumatic Life Events in a Representative Sample of Hospitalized Injured Adolescents and Their Parents
Zatzick et al.
J Pediatr Psychol 2006;31:377-387.
ABSTRACT | FULL TEXT  

Pharmacologic Response to Depressive Disorders Among Adolescents
Sewitch et al.
Psychiatr. Serv. 2005;56:1089-1097.
ABSTRACT | FULL TEXT  

Age Effects on Antidepressant-Induced Manic Conversion
Martin et al.
Arch Pediatr Adolesc Med 2004;158:773-780.
ABSTRACT | FULL TEXT  

Efficacy and safety of antidepressants for children and adolescents
Jureidini et al.
BMJ 2004;328:879-883.
FULL TEXT  

Treating Depression in Children and Adolescents
JWatch Psychiatry 2003;2003:9-9.
FULL TEXT  

Sertraline Is Effective for Childhood Depression
JWatch Pediatrics 2003;2003:3-3.
FULL TEXT  

Treating Depression in Children and Adolescents
JWatch General 2003;2003:4-4.
FULL TEXT